JANG-JAER LEESHIH-JUNG CHENGJIIANG-HUEI JENGCHUN-PIN CHIANGLau H.-P.SANG-HENG KOK2021-07-062021-07-0620111043-3074https://www.scopus.com/inward/record.uri?eid=2-s2.0-80051758404&doi=10.1002%2fhed.21380&partnerID=40&md5=fd72868046c42f01f418803a1f83a0e2https://scholars.lib.ntu.edu.tw/handle/123456789/569696Background. The management of bisphosphonate-related osteonecrosis of the jaws (BRONJ) is challenging and controversial. At present, there is no established medication treatment for the disease. Methods. A 78-year-old osteoporotic woman with osteonecrosis of the mandible related to alendronate therapy was referred for treatment. The disease was unresponsive to conservative therapy, including antibacterial mouth rinse, antibiotics, and minor surgical debridement. Teriparatide, a human recombinant pararthyroid hormone peptide 1-34, was then used for treatment. Results. The oral mucosa completely regrew, and pain subsided 4 weeks after the initiation of teriparatide administration. Progressive bone regeneration was found during and after the 6-month period of teriparatide therapy. Conclusion. Our case demonstrated that teriparatide can be an important adjuvant in the management of advanced BRONJ and should be considered prior to major resection with reconstruction. Its true value in the treatment of BRONJ for noncancer patients with osteoporosis warrants future studies. ? 2010 Wiley Periodicals, Inc. Head Neck, 2010 Copyright ? 2010 Wiley Periodicals, Inc.[SDGs]SDG3alendronic acid; amoxicillin; chlorhexidine; parathyroid hormone[1-34]; adjuvant therapy; aged; article; bisphophonate related osteonecrosis of the jaw; bisphosphonate related osteonecrosis of the jaw; bone density; bone destruction; bone regeneration; case report; conservative treatment; debridement; disease course; drug induced disease; drug withdrawal; female; human; jaw osteonecrosis; mandible; mouth mucosa; osteoporosis; pain; panoramic radiography; patient referral; priority journal; soft tissue inflammation; tissue regeneration; tooth extraction; treatment duration; treatment outcome; Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Regeneration; Debridement; Female; Humans; Teriparatidejournal article10.1002/hed.21380203100422-s2.0-80051758404